Neonatal alloimmune thrombocytopenia

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
1 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
FcRn antagonist 1 substance
Phase III: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

2 trials
  • Janssen - Cilag International Commercial
    NIPOCALIMAB
    2023-504307-88-00 10 countries 2024 n=27
    Recruiting
  • Janssen - Cilag International Commercial
    NIPOCALIMAB
    2023-509434-19-00 4 countries 2025 n=13
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 2 Phase III 2
New trials by year
2024
1
2025
1
← All indication landscapes